Supriya Lifescience saw its shares move up more than 3% in early trade after the company announced its September-quarter (Q2) results. The numbers reflected healthy year-on-year growth across revenue, EBITDA, and net profit, though margins softened slightly. As of 9:41 AM, the shares were trading 3.48% higher at Rs 788.90.
For Q2, the company reported revenue of Rs 200 crore, marking a 20.3% jump from Rs 166 crore last year. The performance was supported by strong demand across key product segments.
EBITDA also improved, coming in at Rs 72.7 crore, up 12.3% from Rs 64.7 crore in the same quarter a year ago. However, the operating margin slipped a bit to 36.4%, compared with 39% previously.
Net profit for the quarter stood at Rs 50.4 crore, registering a 9.3% rise from Rs 46.2 crore last year.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
